Cargando…

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole

Posaconazole is a triazole antifungal agent that has broad-spectrum activity against many yeasts and filamentous fungi, including Candida species, Cryptococcus neoformans, Aspergillus species, and Zygomycetes. This drug has been approved for the prevention of invasive fungal infections in patients w...

Descripción completa

Detalles Bibliográficos
Autor principal:	Soysal, Ahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573198/ https://www.ncbi.nlm.nih.gov/pubmed/26392781 http://dx.doi.org/10.2147/IDR.S65592

Ejemplares similares

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
por: Wiederhold, Nathan P
Publicado: (2015)

Prevention of Invasive Aspergillus Fungal Infections with the Suspension and Delayed-Release Tablet Formulations of Posaconazole in Patients with Haematologic Malignancies
por: Leclerc, Elisabeth, et al.
Publicado: (2018)

Posaconazole in the management of refractory invasive fungal infections
por: Langner, Stefan, et al.
Publicado: (2008)

1469 Posaconazole salvage treatment for invasive fungal infection : a single center experience with utilization of posaconazole oral suspension or delayed-released tablet
por: Kim, Jong Hun, et al.
Publicado: (2014)

Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis
por: Wong, Tse Yee, et al.
Publicado: (2020)

Clinical Outcomes of the Oral Suspension vs Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Tallman, Gregory B, et al.
Publicado: (2017)

Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections
por: Furuno, Jon P., et al.
Publicado: (2018)

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections
por: Zoller, Emily, et al.
Publicado: (2010)

Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection
por: Allegra, Sarah, et al.
Publicado: (2017)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

Evaluation of Serum Posaconazole Concentrations in Patients with Hematological Malignancies Receiving Posaconazole Suspension Compared to the Delayed-Release Tablet Formulation
por: Belling, Morgan, et al.
Publicado: (2017)

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis
por: Leelawattanachai, Pannee, et al.
Publicado: (2019)

Cutaneous Paecilomyces infection in an immunocompromised patient in the setting of postthrombotic syndrome successfully treated with posaconazole
por: Martinez, Edgar, et al.
Publicado: (2020)

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain
por: Cámara, Rafael, et al.
Publicado: (2017)

Refractory invasive aspergillosis controlled with posaconazole and pulmonary surgery in a patient with chronic granulomatous disease: case report
por: Kepenekli, Eda, et al.
Publicado: (2014)

Invasive fungal infection by Peziza ostracoderma in an immunocompromised patient
por: Kinch, Amelie, et al.
Publicado: (2022)

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients
por: Liu, Li, et al.
Publicado: (2023)

Emerging fungal infections in immunocompromised patients
por: Low, Chian-Yong, et al.
Publicado: (2011)

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain
por: Grau, Santiago, et al.
Publicado: (2012)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

2736. Real-world Effectiveness of Posaconazole Prophylaxis in Preventing Invasive Fungal Infections in Recipients of Allogeneic Stem Cell Transplantation
por: Álvarez-Ortega, Carolina, et al.
Publicado: (2023)

Challenges in the Diagnosis of Invasive Fungal Infections in Immunocompromised Hosts
por: Antinori, Spinello, et al.
Publicado: (2018)

Radionuclide Imaging of Invasive Fungal Disease in Immunocompromised Hosts
por: Lawal, Ismaheel O., et al.
Publicado: (2021)

1161. Effectiveness of Posaconazole in the Treatment of Rare Invasive Fungal Infections: A Systematic Literature Review
por: Bernauer, Mark, et al.
Publicado: (2020)

Caspofungin for the Treatment of Immunocompromised and Severely Ill Children and Neonates with Invasive Fungal Infections
por: Wiederhold, Nathan P., et al.
Publicado: (2012)

Safety and efficacy of liposomal amphotericin B for the empirical therapy of invasive fungal infections in immunocompromised patients
por: Miceli, Marisa H, et al.
Publicado: (2012)

Gastric Mucormycosis: An Infection of Fungal Invasion into the Gastric Mucosa in Immunocompromised Patients
por: Naqvi, Haider A., et al.
Publicado: (2020)

Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
por: Van Matre, Edward T., et al.
Publicado: (2019)

Cost-Effectiveness of Posaconazole vs. First-Generation Triazoles for the Prevention of Invasive Fungal Infections Among High-Risk Patients With Hematological Malignancies in China
por: Shi, Changcheng, et al.
Publicado: (2022)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

2546. Administration of Crushed Posaconazole Delayed Release Tablets Failed to Achieve Therapeutic Levels
por: Kane, Nicholas, et al.
Publicado: (2023)

Role of posaconazole in the treatment of oropharyngeal candidiasis
por: Ianas, Voichita, et al.
Publicado: (2010)

Acute invasive fungal sinusitis in immunocompromised children
por: Kebudi, Rejin
Publicado: (2022)

Invasive facial fungal infections: Orofacial soft-tissue infiltration in immunocompromised patients
por: Jun, Peter, et al.
Publicado: (2015)

Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study
por: Chen, Xiaochen, et al.
Publicado: (2021)

Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease
por: McCann, Sean, et al.
Publicado: (2023)

Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient
por: Anderson, Anthony, et al.
Publicado: (2017)

Fungal Infections of the Ear in Immunocompromised Host: a Review
por: Viswanatha, Borlingegowda, et al.
Publicado: (2011)

Role of posaconazole in the management of oropharyngeal and esophageal candidiasis
por: Vazquez, Jose A
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_p9qf0bh3v3dp5f2rjmhgmqnfhu